Streetbeat News

Analyst Ratings

USB

RBC Capital analyst Gerard Cassidy has maintained an Outperform rating on U.S. Bancorp (NYSE:USB) and increased the price target from $43 to $47, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 2:06 pm

REAX

Roth MKM analyst Darren Aftahi has reaffirmed a Buy rating on Real Brokerage (NASDAQ:REAX) and increased the price target from $2.75 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 2:06 pm

EVGO

RBC Capital analyst Chris Dendrinos has reiterated a 'Sector Perform' rating on EVgo (NASDAQ:EVGO) and maintained a price target of $5. This suggests that RBC Capital views EVgo's stock as fairly valued at its current level and does not expect significant price movement in either direction in the near term.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 2:04 pm

BTMD

Roth MKM analyst George Kelly has maintained a Buy rating on Biote (NASDAQ: BTMD) but has reduced the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 2:03 pm

EQT

RBC Capital analyst Scott Hanold has reiterated an Outperform rating on EQT Corporation (NYSE:EQT) and maintained a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 2:02 pm

CFG

RBC Capital analyst Gerard Cassidy has maintained an Outperform rating on Citizens Financial Group (NYSE:CFG) and increased the price target from $33 to $35.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 2:01 pm

CFG

Citizens Financial Group (NYSE:CFG) has been rated by 7 analysts in the last three months, with an average 12-month price target of $33.71, up from $32.83. Ratings range from 'Outperform' to 'Neutral', with recent actions including both raised and lowered price targets. The company faces challenges with a revenue decline of -7.49%, below-average net margin and ROE, and a high debt-to-equity ratio. CFG's market capitalization is above industry average, indicating a strong market position.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 2:00 pm

ITCI

Intra-Cellular Therapies (NASDAQ:ITCI) received mixed analyst ratings with 2 bullish, 5 somewhat bullish, and 1 indifferent. The average 12-month price target is $81.75, up from $75.60, with a high of $101.00 and a low of $64.00. Analysts from firms like Goldman Sachs, Baird, and B of A Securities have adjusted their ratings and price targets, reflecting their views on the company's market position and recent performance. Intra-Cellular Therapies, a biopharmaceutical company, has seen a 75.05% revenue growth rate over 3 months but lags in net margin and ROE compared to industry averages.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 2:00 pm

EA

Stifel analyst Drew Crum has reaffirmed a Buy rating on Electronic Arts (NASDAQ:EA) and increased the price target from $152 to $155. The report was released on January 17, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:59 pm